Last reviewed · How we verify

Autologous Menstrual Blood Stem Cells

Avicenna Research Institute · Phase 3 active Biologic

Autologous Menstrual Blood Stem Cells is a Cell therapy Biologic drug developed by Avicenna Research Institute. It is currently in Phase 3 development for Asherman's syndrome (intrauterine adhesions), Premature ovarian failure / primary ovarian insufficiency.

Autologous menstrual blood-derived stem cells are harvested from a patient's own menstrual fluid and reinfused to promote tissue regeneration and reduce inflammation.

Autologous menstrual blood-derived stem cells are harvested from a patient's own menstrual fluid and reinfused to promote tissue regeneration and reduce inflammation. Used for Asherman's syndrome (intrauterine adhesions), Premature ovarian failure / primary ovarian insufficiency.

At a glance

Generic nameAutologous Menstrual Blood Stem Cells
SponsorAvicenna Research Institute
Drug classCell therapy
ModalityBiologic
Therapeutic areaRegenerative Medicine
PhasePhase 3

Mechanism of action

Menstrual blood contains a population of stem cells (endometrial stem cells) with high proliferative capacity and immunomodulatory properties. When isolated and expanded ex vivo, these autologous cells can differentiate into multiple cell types and secrete anti-inflammatory cytokines, potentially promoting tissue repair and reducing pathological inflammation in target tissues. The autologous nature minimizes immunological rejection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Autologous Menstrual Blood Stem Cells

What is Autologous Menstrual Blood Stem Cells?

Autologous Menstrual Blood Stem Cells is a Cell therapy drug developed by Avicenna Research Institute, indicated for Asherman's syndrome (intrauterine adhesions), Premature ovarian failure / primary ovarian insufficiency.

How does Autologous Menstrual Blood Stem Cells work?

Autologous menstrual blood-derived stem cells are harvested from a patient's own menstrual fluid and reinfused to promote tissue regeneration and reduce inflammation.

What is Autologous Menstrual Blood Stem Cells used for?

Autologous Menstrual Blood Stem Cells is indicated for Asherman's syndrome (intrauterine adhesions), Premature ovarian failure / primary ovarian insufficiency.

Who makes Autologous Menstrual Blood Stem Cells?

Autologous Menstrual Blood Stem Cells is developed by Avicenna Research Institute (see full Avicenna Research Institute pipeline at /company/avicenna-research-institute).

What drug class is Autologous Menstrual Blood Stem Cells in?

Autologous Menstrual Blood Stem Cells belongs to the Cell therapy class. See all Cell therapy drugs at /class/cell-therapy.

What development phase is Autologous Menstrual Blood Stem Cells in?

Autologous Menstrual Blood Stem Cells is in Phase 3.

What are the side effects of Autologous Menstrual Blood Stem Cells?

Common side effects of Autologous Menstrual Blood Stem Cells include Injection site reactions, Infection, Allergic reaction.

Related